September 9, 2019
EA Pharma, a gastrointestinal disease subsidiary of Eisai, and the National Center of Neurology and Psychiatry (NCNP) said on September 6 that they have signed a worldwide exclusive license for all indications of a glycolipid compound produced by bacteria parasitizing...read more